Table 4.
Baseline Characteristics for Patients Who Experienced an Absolute and Relative Reduction in the 6MWT Distance Compared to Those Who Did Not
| Absolute Reduction in 6MWT Distance |
Relative Reduction in 6MWT Distance |
|||||
|---|---|---|---|---|---|---|
| Stable Distance (n = 689; 61.6%) | Reduction >35 m (n = 429; = 38.4%) | P Value | Stable Distance (n = 570; 51.0%) | Reduction >5% (n = 548; 49.0%) | P Value | |
| Baseline characteristics | ||||||
| Age, y | 75.5 ± 8.5 | 74.7 ± 8.2 | 0.038 | 75.0 ± 8.8 | 75.3 ± 8.1 | 0.957 |
| Male | 621 (90.1) | 375 (87.4) | 0.156 | 513 (90.0) | 483 (88.1) | 0.318 |
| Ethnicity | 0.010 | 0.005 | ||||
| White | 574 (83.3) | 83 (19.3) | 482 (84.6)a | 432 (78.8) | ||
| Afro-Caribbean | 106 (15.4) | 83 (19.3) | 80 (14.0)a | 109 (19.9) | ||
| Asian | 9 (1.3) | 2 (0.5) | 8 (1.4) | 3 (0.5) | ||
| Other | 0 (0.0)a | 4 (0.9) | 8 (1.4)a | 3 (0.5) | ||
| Genotypes | <0.001 | 0.001 | ||||
| wtATTR | 530 (76.9)a | 285 (66.4) | 443 (77.7)a | 372 (67.9) | ||
| p.(V142I) hATTR | 77 (11.2)a | 68 (15.9) | 60 (10.5)a | 85 (15.5) | ||
| Non-p.(V142I) hATTR | 82 (11.9)a | 76 (17.7) | 67 (11.8)a | 91 (16.6) | ||
| Heart failure severity | ||||||
| NYHA functional class | 0.039 | 0.252 | ||||
| I | 101 (14.7) | 54 (12.6) | 87 (15.3) | 68 (12.4) | ||
| II | 444 (64.4) | 307 (71.6)a | 374 (65.6) | 377 (68.8) | ||
| III | 125 (18.1) | 61 (14.2) | 97 (17.0) | 89 (16.2) | ||
| IV | 5 (0.7) | 0 (0.0) | 1 (0.2) | 4 (0.7) | ||
| Missing | 14 | 7 | 11 | 10 | ||
| Baseline 6MWT distance, m | 365 (264-438) | 385 (301-448) | 0.005 | 372 (276-450) | 368 (286-434) | 0.842 |
| Baseline percent predicted 6MWT, % | 72.1 ± 25.6 | 78.0 ± 22.2 | 0.004 | 73.3 ± 25.7 | 75.4 ± 23.3 | 0.630 |
| Systolic blood pressure, mm Hg | 126.5 ± 17.0 | 124.5 ± 17.1 | 0.036 | 126.3 ± 16.8 | 125.0 ± 17.3 | 0.144 |
| Diastolic blood pressure, mm Hg | 75.0 ± 10.0 | 73.9 ± 10.5 | 0.019 | 75.1 ± 10.0 | 74.0 ± 10.4 | 0.029 |
| Heart rate, beats/min | 71.7 ± 12.8 | 72.8 ± 14.1 | 0.420 | 71.6 ± 12.9 | 72.7 ± 13.6 | 0.267 |
| Blood biomarkers | ||||||
| NAC stage | 0.220 | 0.109 | ||||
| 1 | 404 (58.6) | 229 (53.4) | 339 (59.5) | 294 (53.6) | ||
| 2 | 215 (31.2) | 149 (34.7) | 177 (31.1) | 187 (34.1) | ||
| 3 | 70 (10.2) | 51 (11.9) | 54 (9.5) | 67 (12.2) | ||
| NT-proBNP, ng/L | 2,313 (1,115-4,030) | 2,436 (1,281-4,224) | 0.135 | 2,286 (1,073-3,958) | 2,461 (1,281-4,263) | 0.018 |
| eGFR, mL/min/1.73 m2 | 62 (52-77) | 60 (48-74) | 0.009 | 63 (52-77) | 59 (48-74) | 0.002 |
| Hemoglobin, g/L | 140 (130-149) | 137 (126-148) | 0.006 | 141 (130-149) | 137 (127-148) | 0.005 |
| Serum total bilirubin, μmol/L | 12 (9-18) | 13 (9-18) | 0.393 | 12 (9-17) | 13 (9-18) | 0.577 |
| Alanine transaminase, IU/L | 25 (19-33) | 25 (19-33) | 0.865 | 25 (19-34) | 25 (19-32) | 0.544 |
| Alkaline phosphatase, IU/L | 87 (69-114) | 87 (68 -115) | 0.967 | 87 (68-114) | 87 (70-115) | 0.517 |
| GGT, IU/L | 63 (30-129) | 70 (33-134) | 0.327 | 62 (31-129) | 70 (32-133) | 0.223 |
| Echocardiographic parameters | ||||||
| IVSd, mm | 16.6 ± 2.5 | 16.8 ± 2.5 | 0.111 | 16.6 ± 2.5 | 16.8 ± 2.5 | 0.112 |
| PWTd, mm | 16.2 ± 2.6 | 16.5 ± 2.6 | 0.074 | 16.1 ± 2.6 | 16.4 ± 2.6 | 0.074 |
| LVEF, % | 49.3 ± 10.6 | 49.5 ± 10.7 | 0.702 | 49.3 ± 10.7 | 49.5 ± 10.5 | 0.628 |
| Longitudinal strain, % | –11.3 ± 3.7 | –11.6 ± 3.6 | 0.181 | –11.3 ± 3.7 | –11.5 ± 3.6 | 0.495 |
| E/e′ | 15.8 ± 7.5 | 16.2 ± 6.5 | 0.171 | 15.6 ± 7.5 | 16.4 ± 6.7 | 0.010 |
Values are mean ± SD, n (%), n, or median (Q1-Q3).
Abbreviations as in Table 1.
a
P values for pairwise comparison < 0.05.